This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Newell to Sell Process Solutions Business for $500 Million
by Zacks Equity Research
Newell (NWL) agrees to sell its Process Solutions business to One Rock Capital Partners, LLC, for $500 million.
Archer Daniels to Expand Citrus Portfolio With Ziegler Buyout
by Zacks Equity Research
Archer Daniels (ADM) to buy Europe-based Ziegler Group to bolster its natural citrus flavor portfolio. This follows the recent buyout of Florida Chemical based in the United States.
Newell's Contigo Launches LUXE, a Spill-Proof Collection
by Zacks Equity Research
Newell's (NWL) Contigo brand launches the LUXE Collection, extending its stainless steel thermal and hydration lines.
Can Kraft Heinz's Potential Sale of Breakstone's Aid Growth?
by Zacks Equity Research
Kraft Heinz (KHC) has appointed Royal Bank of Canada to assess alternatives for its Breakstone's sour cream and cottage cheese business, per sources. This could also involve a potential sale.
Can Newell's (NWL) Transformation Plan Offset Sales Woes?
by Zacks Equity Research
Newell's (NWL) dismal sales surprise trend can be attributed to lower core sales and adverse foreign currency. Nevertheless, its Transformation Plan appear encouraging.
Procter & Gamble Hits 52-Week High: What's Behind the Rally?
by Zacks Equity Research
Procter & Gamble (PG) gains from its solid focus on product improvement, packaging and marketing initiatives, and productivity and cost-savings plan.
Here's Why Investors Should Buy Clorox (CLX) Stock Right Now
by Zacks Equity Research
Clorox (CLX) gains from strategic initiatives including smooth execution of the 2020 Strategy, focus on e-commerce business and brand management efforts.
Friday Rebound Takes the Sting out of a Tough Week
by David Borun
US equity markets recover from a Friday slide but still post their worst week of 2019
Kellogg Down on Soft U.S. Snacks & Morning Foods Businesses
by Zacks Equity Research
Kellogg (K) grapples with high costs related to brand enhancement, stiff competition, adverse currency effects, and weak U.S. snacks and Morning Foods businesses.
Medifast, Eldorado Resorts, Salesforce, Boeing, Starbucks and WPP highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Medifast, Eldorado Resorts, Salesforce, Boeing, Starbucks and WPP highlighted as Zacks Bull and Bear of the Day
Kraft Heinz (KHC) to Expand Customer Base With Farmstead Deal
by Zacks Equity Research
Kraft Heinz (KHC) ties up with online grocer, Farmstead. This is likely to help Kraft Heinz reach more consumers through online orders and deliveries.
Bull of the Day: Medifast (MED)
by David Borun
This innovative weight-loss company is producing better results than household name competitors with its innovative strategy
Archer Daniels Acquires FCC, Boosts Citrus Flavors Portfolio
by Zacks Equity Research
Archer Daniels (ADM) has acquired Florida Chemical's Consumer and Industrial Chemistry Technologies segment for $175 million in cash.
Q4 Earnings Top Estimates, Revenues Miss
by Sheraz Mian
3D Systems Corporation delivered non-GAAP earnings of 10 cents per share for fourth-quarter 2018
Friday Rally Helps the Markets Recover Earlier Weekly Losses
by David Borun
Positive earnings data and an end to the government shutdown help keep the 2019 rally gooing
3 Weight-Loss Stocks in Focus on Rising Obesity Fears
by Sreyoshi Mukherjee
Three companies with bright prospects as the U.S. weight-loss industry keeps up its battle against obesity.
Medifast (MED) Misses Q3 Earnings Estimates
by Zacks Equity Research
Medifast (MED) delivered earnings and revenue surprises of -0.87% and 11.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Medifast (MED) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Medifast (MED) closed the most recent trading day at $214.20, moving +1.19% from the previous trading session.
Medifast (MED) Q3 Earnings: Coaches & OPTAVIA are Key Drivers
by Zacks Equity Research
Medifast's (MED) Q3 performance to gain from a sturdy coach base and advancement in the OPTAVIA brand.
Medifast (MED) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Medifast (MED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medifast (MED) Stock Moves -0.77%: What You Should Know
by Zacks Equity Research
Medifast (MED) closed the most recent trading day at $204.93, moving -0.77% from the previous trading session.
SYY or MED: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SYY vs. MED: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Champions Oncology, General Finance, Tilly's, Armstrong Flooring and Medifast
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Champions Oncology, General Finance, Tilly's, Armstrong Flooring and Medifast
Wall Street Bulls to Flourish in Q4: 5 Solid Growth Picks
by Nalak Das
Despite trade war concerns, a robust U.S. economy and strong earnings results boosted investors' confidence in the stock markets.
Here's Why McCormick (MKC) is Sizzling in the Culinary Space
by Zacks Equity Research
McCormick's (MKC) top line gains from impressive brands performance. Yielding buyouts strengthens portfolio further.